Navigation Links
SynCardia Posts Record Revenue and Profit in Q1 2012
Date:5/17/2012

TUCSON, Ariz., May 17, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced record-setting revenue for the quarter ended March 31, 2012, due in part to Certified Centers performing a record number of implants of the SynCardia temporary Total Artificial Heart.

(Photo: http://photos.prnewswire.com/prnh/20120517/LA08709)

"Q1 was our best quarter to date," said Michael Garippa, SynCardia Chairman/CEO/President. "Compared to the same quarter last year, revenue and implants increased by more than 60%. We also set a new record for implants performed in a single quarter."

Last month, SynCardia recognized three hospitals for their rapid use of the Total Artificial Heart: Texas Heart Institute, which performed its first four implants in 12 days, University of Washington Medical Center, which performed its first four implants in 35 days, and EJK Duisburg in Germany, which performed three implants in 20 days. In February, the Total Artificial Heart surpassed more than 1,000 implants worldwide.

"Our sales were bolstered by new hospitals that identified multiple candidates for the Total Artificial Heart and then implanted these gravely-ill patients in rapid succession," Garippa said. "These centers have continued to deploy the Total Artificial Heart as the new standard of care for end-stage biventricular heart failure."

In April, the number of hospitals that are enrolled in or have completed SynCardia's four-phase certification program surpassed 100. Of these hospitals, 68 have performed their first proctored implant of the Total Artificial Heart to become SynCardia Certified Centers, which now span 15 countries around the world.

Some of the newest SynCardia Certified Centers are pediatric hospitals. In March, Children's Hospital of Philadelphia (CHOP) and Phoenix Children's Hospital bridged their first patients to transplant with the Total Artificial Heart. This marked three consecutive pediatric patients bridged to transplant with the Total Artificial Heart during a six-month period.

On March 2, the U.S. Food and Drug Administration (FDA) approved a Humanitarian Use Device (HUD) designation for the Total Artificial Heart to be used for destination therapy in addition to its current approval as a bridge to transplant. The next step is for SynCardia to submit a Humanitarian Device Exemption (HDE) to the FDA. Once approved, the HDE will allow up to 4,000 U.S. patients annually who are not transplant-eligible to receive the Total Artificial Heart on a permanent basis.

www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart… read more


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SynCardia Nearly Doubles Sales for Second Straight Year in 2011
2. Forbes Names SynCardia One of "Americas Most Promising Companies"
3. Texas Childrens Is First Pediatric Hospital To Begin Certification Process for SynCardias Total Artificial Heart
4. Lillys John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts
5. CryoLife Posts Record Quarterly Revenues of $30.2 Million
6. ImageXpres Posts OTC Markets 2010 Annual Report
7. CryoLife Posts Record Annual Revenues of $116.6 Million
8. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
9. Biotech Posts Weak Performance in April
10. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
11. Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):